The gene therapy sector, once a beacon of hope for revolutionary treatments, has seen a significant slowdown in investment post the COVID-19 pandemic. This downturn follows a period of unprecedented financial influx during the pandemic years, raising questions about the future of this promising
The biopharma industry, renowned for its rapid innovation and significant contributions to healthcare, currently faces a tumultuous period marked by widespread layoffs. From early 2023 through late 2024, numerous companies have announced substantial workforce reductions, which reflect a time of
South Korea's pharmaceutical and biotech industry is witnessing a fascinating shift as Contract Development and Manufacturing Organizations (CDMOs) and biosimilar developers are experiencing robust growth, while traditional pharmaceutical companies lag. At the forefront of this transition is
Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to
In October 2023, Sanofi, a leading global pharmaceutical company, announced a major shift in its business strategy. This shift involved the separation of its consumer health division, a move set to be completed in 2024. Historically, Sanofi's consumer health division, which includes popular
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing